• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by CONMED Corporation

    4/8/25 4:07:46 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CNMD alert in real time by email
    DEFA14A 1 d877226ddefa14a.htm DEFA14A DEFA14A
    Table of Contents

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☑

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    CONMED CORPORATION

    (Name of Registrant as Specified In Its Charter)

    Payment of Filing Fee (Check the appropriate box):

     

    ☑

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     


    Table of Contents

    LOGO

    styleINA P.O. BOX 8016, CARY, NC 27512-9903 Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders CONMED Corporation Meeting To Be Held On May 20, 2025 For Stockholders of record as of March 24, 2025 Annual Meeting of Stockholders To order paper materials, use one of the Tuesday, May 20, 2025 1:30 PM, Eastern Daylight Time CONMED Headquarters 11311 Concept Blvd., Largo, FL 33773 and live via the Internet. Please following methods. visit www.proxydocs.com/CNMD for more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/CNMD Internet: For a convenient way to view proxy materials, VOTE, and obtain www.investorelections.com/CNMD directions to attend the meeting go to www.proxydocs.com/CNMD To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. Call: 1-866-648-8133 This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Email: [email protected] Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the * If requesting material by e-mail, please send a blank e-mail with the internet. 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your If you want to receive a paper or e-mail copy of the proxy material, you must request one. e-mail requesting material. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before May 9, 2025. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved


    Table of Contents

    LOGO

    CONMED Corporation Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1, 2, 3 AND 4 PROPOSAL 1. To elect eight directors to serve on the Company’s Board of Directors. 1.01 Patrick Beyer 1.02 David Bronson 1.03 Brian P. Concannon 1.04 LaVerne Council 1.05 Charles M. Farkas 1.06 Martha Goldberg Aronson 1.07 Mark Kaye 1.08 Barbara J. Schwarzentraub 2. Advisory Vote on Named Executive Officer Compensation; 3. To approve the 2025 Long-Term Incentive Plan; 4. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025; 5. To transact such other business as may properly be brought before the meeting or any adjournment or postponement thereof.

    Get the next $CNMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNMD

    DatePrice TargetRatingAnalyst
    6/12/2025Buy → Hold
    Needham
    4/28/2025$55.00Buy → Hold
    Stifel
    2/6/2025$85.00 → $70.00Overweight → Neutral
    Analyst
    2/1/2024$119.00 → $129.00Buy
    Needham
    5/22/2023$140.00Buy
    CL King
    3/27/2023$124.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/21/2023$96.00Equal Weight
    Wells Fargo
    10/12/2022$85.00Hold
    Jefferies
    More analyst ratings

    $CNMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results

    CONMED Corporation (NYSE:CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 Highlights Sales of $373.2 million increased 7.9% year-over-year as reported and 7.1% in constant currency. Domestic revenue increased 1.4% year-over-year. International revenue increased 17.0% year-over-year as reported and 15.4% in constant currency. Diluted net earnings per share (GAAP) were $0.54, compared to diluted net earnings per share (GAAP) of $1.08 in the fourth quarter of 2024. Adjusted diluted net earnings per share(1) were $1.43, compared to adjusted diluted net earnings per share of $1.34 in the fourth quarter of 2

    1/28/26 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation Announces Chief Financial Officer Transition

    Todd Garner to step down as CONMED's CFO, effective March 15, 2026, and remain In an Advisory Role Through November 2, 2026 Company Initiates Comprehensive Search for Next Chief Financial Officer CONMED Reaffirms Full-Year 2025 Revenue and Adjusted EPS Outlook CONMED Corporation (NYSE:CNMD) today announced the departure of Todd Garner from his role as Chief Financial Officer effective March 15, 2026. To ensure a smooth and orderly transition, Mr. Garner will remain with the Company in an advisory capacity through November 2, 2026. CONMED has initiated a comprehensive search process, supported by a leading executive search firm, to identify its next Chief Financial Officer. "On beh

    1/8/26 4:55:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference

    CONMED Corporation (NYSE:CNMD) today announced that Patrick J. Beyer, President and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT (6:00 p.m. ET) on Monday, January 12, 2026 in San Francisco, CA. A live audio webcast of the presentation will be accessible through the "Investors" section of the Company's website at www.conmed.com and will be available for replay following the event. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and o

    1/5/26 4:10:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    SEC Filings

    View All

    CONMED Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CONMED Corp (0000816956) (Filer)

    1/28/26 4:13:44 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - CONMED Corp (0000816956) (Filer)

    1/12/26 9:00:45 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - CONMED Corp (0000816956) (Filer)

    1/8/26 5:00:51 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lalomia Brent acquired $1,284 worth of shares (32 units at $40.60) (SEC Form 5)

    5 - CONMED Corp (0000816956) (Issuer)

    1/8/26 11:29:11 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Information Officer Glaze Richard sold $10,591 worth of shares (257 units at $41.21), closing all direct ownership in the company (SEC Form 4)

    4 - CONMED Corp (0000816956) (Issuer)

    11/24/25 1:18:01 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Information Officer Glaze Richard converted options into 375 shares and covered exercise/tax liability with 118 shares (SEC Form 4)

    4 - CONMED Corp (0000816956) (Issuer)

    11/21/25 3:39:45 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Bronson David M bought $97,322 worth of shares (1,350 units at $72.09), increasing direct ownership by 9% to 16,460 units (SEC Form 4)

    4 - CONMED Corp (0000816956) (Issuer)

    5/14/24 3:37:54 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Schwarzentraub Barbara J bought $99,873 worth of shares (1,442 units at $69.26) (SEC Form 4)

    4 - CONMED Corp (0000816956) (Issuer)

    5/10/24 5:29:04 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Aronson Martha Goldberg bought $141,960 worth of shares (2,000 units at $70.98) (SEC Form 4)

    4 - CONMED Corp (0000816956) (Issuer)

    5/8/24 4:20:48 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CONMED downgraded by Needham

    Needham downgraded CONMED from Buy to Hold

    6/12/25 7:52:09 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED downgraded by Stifel with a new price target

    Stifel downgraded CONMED from Buy to Hold and set a new price target of $55.00

    4/28/25 8:32:52 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED downgraded by Analyst with a new price target

    Analyst downgraded CONMED from Overweight to Neutral and set a new price target of $70.00 from $85.00 previously

    2/6/25 7:05:01 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Financials

    Live finance-specific insights

    View All

    CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results

    CONMED Corporation (NYSE:CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2025. Fourth Quarter 2025 Highlights Sales of $373.2 million increased 7.9% year-over-year as reported and 7.1% in constant currency. Domestic revenue increased 1.4% year-over-year. International revenue increased 17.0% year-over-year as reported and 15.4% in constant currency. Diluted net earnings per share (GAAP) were $0.54, compared to diluted net earnings per share (GAAP) of $1.08 in the fourth quarter of 2024. Adjusted diluted net earnings per share(1) were $1.43, compared to adjusted diluted net earnings per share of $1.34 in the fourth quarter of 2

    1/28/26 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation to Announce Fourth Quarter 2025 Financial Results on January 28, 2026

    CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the fourth quarter 2025 after the market close on Wednesday, January 28, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a me

    1/5/26 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CONMED Corporation Announces Third Quarter 2025 Financial Results

    CONMED Corporation (NYSE:CNMD) today announced financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Sales of $337.9 million increased 6.7% year-over-year as reported and 6.3% in constant currency. Domestic revenue increased 5.9% year-over-year. International revenue increased 7.8% year-over-year as reported and 6.8% in constant currency. Diluted net earnings per share (GAAP) were $0.09, compared to diluted net earnings per share (GAAP) of $1.57 in the third quarter of 2024. Adjusted diluted net earnings per share(1) were $1.08, compared to adjusted diluted net earnings per share of $1.05 in the third quarter of 2024. Subsequent to

    11/5/25 4:05:00 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $CNMD
    Leadership Updates

    Live Leadership Updates

    View All

    CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

    CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti

    5/21/25 7:03:00 AM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Beta Bionics Announces the Appointment of Martha Goldberg Aronson as Chair of Its Board of Directors

    CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am

    2/9/21 4:01:00 PM ET
    $CSII
    $MEI
    $CNMD
    Medical/Dental Instruments
    Health Care
    Electrical Products
    Technology

    $CNMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CONMED Corporation

    SC 13G/A - CONMED Corp (0000816956) (Subject)

    11/13/24 4:22:22 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by CONMED Corporation

    SC 13G/A - CONMED Corp (0000816956) (Subject)

    11/12/24 12:53:28 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by CONMED Corporation (Amendment)

    SC 13G/A - CONMED Corp (0000816956) (Subject)

    2/13/24 5:02:29 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care